VABO PHARMA
ActiveVABO PHARMA has been active since 1980 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €166k and a net result of €31k. Equity remains stable across the filed fiscal years (±2.2% per year). Its solvency ranks better than 27% of 10310 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Checked score
Score 2025
55
/ 100
Fair
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability62▼-23
Solvency42▲+2
Growth78=
Track record100
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €9k at 30 days acceptable
Liquidity short (current ratio 0.68 against 0.84 in 2024; short-term debt: 80.7% and cash: 6.8% of total assets), and 82.7% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
17.3%
Return on assets
3.2%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 23-07-2026, 8 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
8 d early
2024
3 d early
2023
1 d early
2022
28 d late
2021
33 d early
2020
31 d late
2019
60 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
19-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€166k▲ 0.4%
2024 · €166k
2018: €145k
2019: €147k
2020: €148k
2021: €154k
2022: €159k
2023: €161k
2024: €166k
2018 → 2025
Total assets
€961k▼ 10.1%
2024 · €1.07M
2018: €1.00M
2019: €1.14M
2020: €1.36M
2021: €1.27M
2022: €1.65M
2023: €1.41M
2024: €1.07M
2018 → 2025
Net result
€31k▼ 78.0%
2024 · €139k
2018: €17k
2019: €177k
2020: €281k
2021: €236k
2022: €330k
2023: €268k
2024: €139k
2018 → 2025
Working capital
€-245k▼ 135%
2024 · €-105k
2018: €24k
2019: €38k
2020: €22k
2021: €47k
2022: €-24k
2023: €-80k
2024: €-105k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€154k-€159k▲ 3.2%€161k▲ 1.7%€166k▲ 2.7%€166k▲ 0.4%
Operating result€238k-€333k▲ 39.7%€278k▼ 16.5%€136k▼ 50.9%€27k▼ 80.4%
Net result€236k-€330k▲ 39.9%€268k▼ 18.9%€139k▼ 48.0%€31k▼ 78.0%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result has fallen three years in a row; 2025 is 80% below 2024 and is the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €961k
Fixed assets
€431k▼ 16.5%
Current assets
€530k▼ 4.2%
Equity and liabilities €961k
Equity
€166k▲ 0.4%
Debt
€795k▼ 12.0%
The debt ratio falls from 84.5% to 82.7%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€111k▼
2024 · €220k
Cash flow
€115k▼
2024 · €223k
Solvency
17.3%▲
2024 · 15.5%
Current ratio
0.68▼
2024 · 0.84
Quick ratio
0.37▼
2024 · 0.47
Debt / equity
4.78▼
2024 · 5.45
ROE
18.4%▼
2024 · 84.1%
ROA
3.2%▼
2024 · 13.0%
Interest coverage
4.75▼
2024 · 10.15
Debt
€795k▼
2024 · €903k
Debt ≤ 1 year
€775k▲
2024 · €657k
Debt > 1 year
€0▼
2024 · €243k
Income taxes
€2k▼
2024 · €3k
Staff costs
€210k▼
2024 · €227k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€1.07M€961k▼
Fixed assets21/28€516k€431k▼
Tangible fixed assets22/27€513k€431k▼
Land and buildings22€414k€385k▼
Plant, machinery and equipment23€99k€45k▼
Furniture and vehicles24-€2k
Financial fixed assets28€3k€27▼
Current assets29/58€553k€530k▼
Stocks and contracts in progress3€243k€244k▲
Stocks30/36€243k€244k▲
Amounts receivable within one year40/41€203k€211k▲
Trade receivables40€89k€82k▼
Other amounts receivable41€114k€129k▲
Cash at bank and in hand54/58€99k€65k▼
Deferred charges and accrued income490/1€8k€10k▲
Equity and liabilities
Total equity and liabilities10/49€1.07M€961k▼
Equity10/15€166k€166k▲
Contributions10/11€50k€50k=
Reserves13€116k€116k▲
Tax-exempt reserves132€3k€3k=
Distributable reserves133€112k€113k▲
Profit (loss) carried forward14€0€0=
Amounts payable17/49€903k€795k▼
Amounts payable after more than one year17€243k€0▼
Financial debts170/4€243k€0▼
Amounts payable within one year42/48€657k€775k▲
Current portion of amounts payable after more than one year42€105k€0▼
Financial debts43€15k€12k▼
Credit institutions430/8€15k€12k▼
Trade debts44€138k€160k▲
Suppliers440/4€138k€160k▲
Taxes, remuneration and social security45€39k€25k▼
Taxes450/3€8k€5k▼
Remuneration and social security454/9€31k€20k▼
Other amounts payable47/48€361k€578k▲
Accrued charges and deferred income492/3€3k€19k▲
Income statement
Code20242025
Remuneration, social security and pensions62€227k€210k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€84k€84k▲
Other operating charges640/8€4k€4k▲
Non-recurring operating charges66A-€48k
Gross operating margin9900€451k€372k▼
Operating profit (loss)9901€136k€27k▼
Financial income75/76B€28k€29k▲
Recurring financial income75€28k€29k▲
Financial charges65/66B€22k€23k▲
Recurring financial charges65€22k€23k▲
Profit (loss) for the period before taxes9903€143k€33k▼
Income taxes67/77€3k€2k▼
Profit (loss) for the period9904€139k€31k▼
Profit (loss) for the period to be appropriated9905€139k€31k▼
Appropriation of the result
Profit (loss) to be appropriated9906€139k€31k▼
Transfer to equity691/2€4k€624▼
To other reserves6921€4k€624▼
Profit to be distributed694/7€135k€30k▼
Directors or managers695€135k€30k▼
Social balance
Average headcount (FTE)90873.53.1▼
The notes to these accounts (19 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
23-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
28-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
30-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
28-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 28 days late
2022
31-12
Financial
Highest result since 2018net €330k ▲39.9%
Operating result €333k, net result €330k, both a record.
28-06
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Equity above €150kEq €154k ▲4%
4 profitable years in a row build equity to €154k.
31-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 31 days late
2020
29-09
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema · 60 days late
2019
25-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
28-06
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
31-08
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 31 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
5 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Menen · 1 establishment unit since 1980
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Dronckaertstraat 68 B8930 MenenGround area
463 m²
Building footprint
126 m²
Volume, LiDAR
524 m³
Parcel 34032B0043/00R000, Flanders · tallest building 8.1 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
Vabo Pharma
since 19802.018.513.382
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 34032B0043/00R000 | Flanders | 463 m² | 1 · 125 m² | 8.1 m · 1 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Food safety, FASFC
1 siteMenen2.018.513.382
Similar companies · same sector, comparable size
PHARMACIE BASILIQUE
BE 0821.770.142
Koekelberg · Eq €166k
PHARMACIE REMILI-BASTIN
BE 0872.727.608
Chapelle-lez-Herlaimont · Eq €166k
VERZELE PHARMA
BE 0896.764.703
Oudenaarde · Eq €166k
CIEL PHARMA
BE 0690.987.220
Brussel · Eq €166k
APOTHEEK VAN DE WALLE-BLANCQUAERT
BE 0864.315.431
Gent · Eq €167k
Of 5,223 companies in sector 47730 we hold annual accounts for 3,862. 3,576 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded02-01-1980
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
52310
47750Retail sale of cosmetics and toilet articles
Sources
Crossroads Bank for EnterprisesNational Bank · 44 filingsAddress and cadastre registers
Data from official sources, last processed on 18-09-2026. Scores and ratios are computed by Checked and are not a credit decision.